冠心病患者血浆髓过氧化物酶与高密度脂蛋白胆固醇的关系

[目的]探讨血浆髓过氧化物酶(MPO)与急性冠脉综合征(ACS)的关系以及影响它们之间关系的因素,以寻找预测ACS的联合标志物.[方法]将本院66例诊断为冠心病的患者研究分为ACS组(36例)、稳定型心绞痛组(SAG,30例).20例冠脉造影正常者为对照组(CG).测定、比较各组研究对象的血浆MPO水平和高密度脂蛋白胆...

Correlation of Plasma Myeloperoxidase and High Density Lipoprotein-cholesterol Level in Patients with Coronary Heart Disease

[Objective]To explore the relationship between plasma myeloperosidase（MPO） and acute coronary syndrome（ACS） and their influential factors in order to search the combination biomarkers for predicting ACS. [Methods]Sixty six patients diagnosed as coronary artery disease（CAD） in our hospital were divided into ACS groul3（ n = 36） and stable angina pectoris（SAP） group（ n = 30）. Twenty patients with normal coronary angiogra- phy were enrolled in the control group. Plasma MPO and HDL-C of all subjects in each group were measured and compared. The relationship between MPO and HDL-C was analyzed. The correlation between MPO and other blood lipids, traditional risk factors was also analyzed at the same time. [Results] Plasma MPO level of ACS group was significantly higher than that of both SAP group and normal control group（ P 〈0.01）, and there was no significant difference between SAP group and normal control group （ P 〉0.05）. Linear correlation analysis showed that MPO was negatively correlated with HDL-C, and not related with LDL-C. There was no significant difference in MPO between ACS group and control group（ P 〉0.05） while HDL-C≥1mmol/l. There was signifi- cant difference in MPO between ACS group and control group（ P 〈0.01） while HDL-C〈1mmol/L. The eorrela tion between MPO and HDL C in low HDL-C group（r =- 0.76, P 〈0.01） was stronger than that in high HDL C group（r= -0.57, P 〈0.01）. MPO was slightly related with hsCRP. Plasma MPO was independent of traditional risk factors such as sex, age, the history of smoking, diabetes and hypertension. [Conclusion] Plasma MPO level in ACS patients is increased significantly. HDL-C level can affect the relationship between MPO and coronary heart disease. MPO and HDL-C can be the combination biomarkers for ACS.